儿科患者中对碳青霉烯类不敏感肠杆菌科细菌耐药性和耐药基因的研究

目的 研究儿科临床分离的对碳青霉烯类抗生素不敏感的肠杆菌科细菌耐药性和产生碳青霉烯酶的耐药基因特征.方法 收集2008年1月至2010年12月北京儿童医院住院患儿分离出的46株对碳青霉烯类抗生素不敏感的肠杆菌科细菌.使用琼脂稀释法进行药敏试验,测定抗菌药物的最低抑菌浓度(MIC)值,按照临床实验室标准化研究所(CLSI) 2011年推荐标准判断结果.使用改良Hodge试验和双纸片协同试验,进行产碳青霉烯酶的表型确证.使用PCR方法进行碳青霉烯酶相关耐药基因的检测.采用WHONET5.6软件进行数据分析.结果 46株对碳青霉烯类抗生素不敏感的肠杆菌科细菌,26株为肺炎克雷伯菌,占56.5％,13株为阴沟肠杆菌,占28.3％,7株为大肠埃希菌,占15.2％.对亚胺培南和美罗培南不敏感率分别为肺炎克雷伯菌69.2％和80.8％,阴沟肠杆菌76.9％和100％,大肠埃希菌85.7％和100％.46株肠杆菌科细菌,改良Hodge试验阳性40株(87.0％),双纸片协同试验阳性41株(89.1％).IMP基因阳性38株(82.6％),其余8株均未扩增出特异性条带检测均为阴性.结论 目前儿科临床分离对碳青霉烯类抗生素不敏感菌株中,肺炎克雷伯菌最多,占56.5％.肺炎克雷伯菌、阴沟肠杆菌和大肠埃希菌对碳青霉烯类抗生素亚胺培南不敏感程度低于美罗培南,对碳青霉烯不敏感肠杆菌科细菌主要产生B类金属酶,均为IMP基因型.     

Carba NP试验及Carba NP-direct试验检测产碳青霉烯酶肠杆菌的临床意义

目的：评价Carba NP试验及Carba NP-direct试验对碳青霉烯类耐药的肠杆菌科细菌碳青霉烯酶检测的临床价值。方法：收集南京医科大学附属无锡市第二人民医院2013年1月至2015年12月临床分离的各种标本耐碳青霉烯类抗生素的肠杆菌科细菌112株,同时选取碳青霉烯敏感的菌株100株作为对照组。所有菌株进行碳青霉烯酶耐药基因PCR检测、改良Hodge试验(MHT试验)、Carba NP试验(CNPt)以及Carba NP-direct(CNPt-d)试验检测。结果：碳青霉烯类耐药的肠杆菌科细菌共112株,92株携带blaKPC-2;8株携带blaNDM-1;1株携带blaVIM-2;1株携带blaIMP-4;10株不携带碳青霉烯酶基因;未检测到携带D组碳青霉烯酶基因的肠杆菌科细菌。以PCR检测的结果为标准,Carba NP试验、Carba NP-direct试验诊断菌株是否产碳青霉烯酶的敏感性和特异性均100%;改良Hodge试验诊断菌株是否产碳青霉烯酶敏感性为96%,特异性为98%。Carba NP试验及Carba NP-direct试验均在2 h内完成检测。结论：Carba NP试验和Carba NP-direct试验均能快速、准确筛查出产碳青霉烯酶的肠杆菌科细菌。Carba NP-direct试验相比Carba NP试验成本低、反应快、结果更明确,可作为表型确认实验和耐药监测的手段。     

大肠埃希菌对碳青霉烯类药物的耐药机制研究

目的 研究我院普外科重症监护病房(ICU)出现的对碳青霉烯类抗菌药物耐药的大肠埃希菌分子流行病学特征和碳青霉烯耐药机制.方法 采用琼脂稀释法检测分离株的抗菌药物敏感性,采用脉冲场琼脂糖凝胶电泳(PFGE)研究碳青霉烯类耐药的大肠埃希菌分子流行病学机制,采用特异性PCR、DNA测序分析、接合试验、质粒提取和质粒转化试验、外膜蛋白分析等技术研究碳青霉烯耐药的分子机制.结果 我院分离的14株碳青霉烯耐药菌分别属于10个流行克隆型,均表现对包括亚胺培南和美罗培南在内多种抗菌药物耐药,碳青霉烯类耐药基因扩增显示均携带KPC-2型碳青霉烯酶基因,质粒提取与转化试验显示KPC-2定位于约56 kb大小的质粒上,SDS-PAGE分析发现耐药株多出现外膜蛋白的改变.结论 我院出现多个流行克隆型的碳青霉烯类耐药的大肠埃希菌,质粒型碳青霉烯酶KPC-2是我院泛耐型大肠埃希菌介导对碳青霉烯类耐药的主要原因,外膜孔蛋白改变参与介导大肠埃希菌对碳青霉烯类高度耐药.     

摩根摩根菌中质粒介导KPC-2型碳青霉烯酶的检测

目的 研究碳青霉烯耐药摩根摩根菌的分子流行病学及其耐药机制.方法 2010年10月-2011年2月从杭州市中医院分离到7株碳青霉烯不敏感的摩根摩根菌.脉冲场凝胶电泳(PFGE)分析菌株之间的同源性;琼脂稀释法测定抗生素对细菌的最低抑菌浓度(MIC);接合试验、质粒图谱分析、特异性PCR扩增和序列分析等研究细菌对碳青霉烯耐药的分子机制.结果 分离自急诊监护病房的6株摩根摩根菌PFGE条带完全相同或相差1～3个条带;分离自重症监护病房的1株摩根摩根菌与其他6株PFGE条带差异明显.7株摩根摩根菌的耐药模式基本相同.亚胺培南、美罗培南和厄他培南的MIC值差异较大,分别为8μg/ml(耐药)、1μg/ml(敏感)和0.25～0.50μg/ml(敏感或中介耐药).7株摩根摩根菌对青霉素类、氨曲南和环丙沙星耐药,对头孢菌素类耐药或敏感,对阿米卡星敏感.接合试验使大肠埃希菌EC600对碳青霉烯类抗生素由敏感变为耐药,对其他β-内酰胺类抗生素也均耐药.摩根摩根菌及转移接合子均含有一个约为60kb的质粒.PCR扩增及测序表明摩根摩根菌及转移接合子均产KPC-2型碳青霉烯酶,且携带qnrS1基因.结论 首次在摩根摩根菌中检测到KPC-2型碳青霉烯酶,KPC-2是引起摩根摩根菌对碳青霉烯类不敏感的主要原因.     

质粒介导KPC-2型碳青霉烯酶肺炎克雷伯菌儿童分离株耐药基因研究

目的 研究碳青霉烯类耐药肺炎克雷伯菌临床儿童分离株的耐药特点及分子流行病学特征.方法 收集温州医学院附属第二医院2010年7月-2011年6月从儿童标本中分离的耐碳青霉烯类肺炎克雷伯菌12株,所有菌株为非重复菌株,菌种鉴定采用全自动微生物分析仪.改良的Hodge试验筛选产碳青霉烯酶阳性菌株,采用PCR法检测KPC、IMP、bla(s)、VIM、SPM和整合酶基因,测序确定基因型.对菌株进行质粒结合试验、质粒消除试验检测质粒的转移性.脉冲场凝胶电泳(PFGE)分析耐药菌株的同源性.结果 12株耐碳青霉烯类肺炎克雷伯菌对庆大霉素、妥布霉素、阿米卡星、环丙沙星、左氧氟沙星、复方磺胺甲噁唑的敏感率分别为8.3％、41.7％、58.3％、8.3％、8.3％、33.3％;12株菌均携带有KPC-2基因,且同时携带有TEM-1和SHV型β-内酰胺酶基因,其中SHV-11-like和SHV-1 2-like各6株;11株携带CTX-M型基因,其中4株为CTX-M-14-like基因,6株CTX-M-15-like基因;2株携带有OXA-10型基因,1株携带有PER-1基因.未检出NDM-1、GIM、SPM、SIM、VIM型碳青霉烯酶基因.12株均为Ⅰ类整合酶基因(int1)阳性.2株通过接合试验把质粒传递给受体菌EC600.所有接合子blaTEM-1基因阳性、超广谱β-内酰胺酶(ESBL)基因阳性及对亚胺培南、庆大霉素、阿米卡星、妥布霉素和头孢噻肟耐药,接合子ESBL基因型与供菌一致.2株菌经质粒消除后对亚胺培南的MIC值均有较大程度降低,消除后KPC-2基因扩增为阴性.12株KPC-2基因阳性菌株经PFGE分成5个基因型,主要为B型和C型.结论 KPC-2型碳青霉烯酶基因已经在儿童肺炎克雷伯菌中播散,常伴随携带多种类型的ESBL基因和Ⅰ类整合酶基因,部分耐药基因可通过质粒播散.     

同时产ArmA型16S rRNA甲基化酶及KPC-2型β-内酰胺酶泛耐药阴沟肠杆菌的研究

目的 探讨上海交通大学医学院附属瑞金医院分离的5株泛耐药阴沟肠杆菌产碳青霉烯酶及16S rRNA甲基化酶的情况及两者之间的相关性.方法 用E test法检测5株泛耐药阴沟肠杆菌对10种抗菌药物的MIC值.PCR扩增16S rRNA甲基化酶基因armA、mtA、rmtB、rmtC、rmtD、npmA,β-内酰胺酶基因TEM、SHV、CTX-M-1、CTX-M-2、CTX-M-8、CTX-M-9、CTX-M-25、PER-1、VEB-1.鸟枪克隆法克隆碳青霉烯酶基因,并对克隆片段进行测序.质粒接合试验验证碳青霉烯酶基因及16S rRNA甲基化酶基因是否具有转移性.脉冲场凝胶电泳(PFGE)法对5株菌进行分子分型.等电聚焦电泳法检测β-内酰胺酶等电点.Southern杂交法对耐药决定因子进行定位.结果 5株阴沟肠杆菌对10种抗菌药物的MIC值均＞32 mg/L.克隆的碳青霉稀酶基因为blaKPC-2,酶编码基因上游为一转座酶基因,两侧为复制靶位,下游为ISKpn6的插入序列,该序列包括一个重复序列和tnpA转座子,酶编码基因位于54.2 kb的一个非接合性大质粒上.等电聚焦电泳显示5株菌均产4种β-内酰胺酶(TEM-1,pI5.4;KPC-2,pI6.7;SHV-12,pI8.2;CTX-M-14,pI8.4).16S rRNA甲基化酶基因位于接合性质粒上,而blaKPC-2基因则位于非接合性质粒上,5株菌PFGE型别一致.结论 5株泛耐药阴沟肠杆菌对碳青霉烯类耐药由产碳青霉烯酶KPC-2所介导.blaKPC-2与armA型16S rRNA甲基化酶基因由两条不同的质粒编码,不存在相关性.临床医院应加强监控,以防止交叉感染.     

肠杆菌科细菌产碳青霉烯酶研究进展

碳青霉烯类抗生素抗菌谱广,抗菌活性强,杀菌作用快,尤其适用于治疗由产超广谱β内酰胺酶(ESBLs)或(和)头孢菌素酶(AmpC)细菌所引起的严重感染.既往临床上常见的耐碳青霉烯类抗生素菌株为以绿脓假单胞菌和不动杆菌属细菌为代表的非发酵细菌,但随着碳青霉烯类抗生素在临床上的广泛使用,耐碳青霉烯类抗生素的肠杆菌科菌株逐渐增加,给临床治疗带来了极大困难.肠杆菌科细菌对碳青霉烯类抗生素耐药的主要机制为产生碳青霉烯酶,现回顾近年的相关研究,就肠杆菌科细菌产碳青霉烯酶的研究进展及其检测方法、耐药菌株的治疗等做一综述.     

重症医学科染KPC-2肺炎克雷伯菌的耐药情况分析及同源性研究

目的重症医学科染KPC-2肺炎克雷伯菌的耐药及同源性情况。方法从2018年4月至2019年2月于我院重症医学科室治疗的患者中提取40例耐碳青霉烯类肺炎克雷伯菌(CRKPN)菌株,对待测菌株进行药敏性试验、mCIM(改良碳青霉烯灭活试验)和eCIM(EDTA改良碳青霉烯灭活试验)联合试验,采用PCR扩增法检测待测菌的耐药基因并进行基因序列检测,采用PFGE对待测菌进行同源性分析。结果在16种抗菌药中,待测菌仅对阿米卡星(27.50%)、庆大霉素(17.50%)、妥布霉素(25.00%)、替加环素(100.00%)以及复方新诺明(55.00%)有敏感性;mCIM和eCIM试验结果显示40株CRKPN均产丝氨酸碳青霉烯酶;PCR试验结果显示待测菌株携带KPC基因阳性率为100%;选择ICU分离的17株CRKPN做PFGE,同源性结果分析显示该病区存在耐碳青霉烯肺炎克雷伯的克隆传播。结论我院重症医学科分离的CRKPN细菌的耐药机制是产丝氨酸碳青霉烯酶,酶基因为KPC-2型,PFGE结果分析显示我院重症医学科存在耐碳青霉烯肺炎克雷伯的克隆传播,需要加强院感监控工作。     

碳青霉烯类药物耐药的弗劳地枸橼酸杆菌耐药机制研究

目的 对耐碳青霉烯类弗劳地枸橼酸杆菌进行同源性分析及多种耐药基因的检测.方法 用琼脂稀释法测定其最低抑菌浓度( MIC)值,采用脉冲场凝胶电泳(PFGE)分析耐碳青霉烯类弗劳地枸橼酸杆菌的同源性,以聚合酶链反应(PCR)检测β-内酰胺酶、膜孔蛋白的缺失等多种耐药基因.结果 PFGE显示1、2、4、5号菌株均有19个条带,具有同源性;PCR试验检测结果1、4号菌携带blaCTX-M型超广谱β-内酰胺酶(ESBLs);2、3、5号菌携带携带blaDHA,3号携带bla ACT/MIR型AmpC 基因,1、2、4、5号菌携带bla KPC-2碳青霉烯酶基因;2号、4号菌株缺失膜孔蛋白基因ompF,3号菌株同时缺失ompC和ompF;其中3号菌株的16S rRNA基因定量确定AmpC基因的表达为阴性菌的106.7倍.结论 宁波市第一医院碳青霉烯类耐药的弗劳地枸橼酸盐杆菌具有同源性,其耐药机制由KPC酶、AmpC酶、ESBLs、膜孔蛋白缺失等共同作用所形成,多数耐药基因定位在质粒上易引起耐药性的播散,临床应引起高度重视.     

我院耐碳青霉烯类阴沟肠杆菌耐药机制与同源性分析

目的 调查耐碳青霉烯类阴沟肠杆菌(CRECL)中携带耐药基因类型与可移动遗传元件存在情况并对耐药菌株进行同源性分析。方法 收集2016年至2020年收集的52株临床分离的CRECL,通过PCR扩增、序列分析与多位点测序分型,确定其碳青霉烯耐药基因类型与菌株分子分型,检测菌株携带整合子、转座子、插入序列与接合质粒遗传标记基因等可移动遗传元件。结果 收集的52株CRECL共有4种ST型,分别为ST93型32株,ST90型14株,ST88型4株,ST177型2株。45株CRECL携带bla_NDM-1基因,14株携带bla_OXA-48基因,还检出有bla_KPC、bla_IMP与bla_VIM耐药基因。49株阴沟肠杆菌均检出整合酶基因IntI 1,47株阴沟肠杆菌检出插入序列ISEcp1。结论 我院CRECL主要的耐碳青霉烯酶基因为bla_NDM-1和bla_OXA-48基因,ST 93型为主要流行基因型。主要的可移动基因元件为Ⅰ类整合子和插入序列IS...     

Identification of blaKPC-2 on different plasmids of three Morganella morganii isolates

Three Morganella morganii strains resistant to carbapenems were recovered from the surgical intensive care unit (SICU) in our hospital. Carbapenemases and extended-spectrum β-lactamases (ESBLs) were respectively detected by the modified Hodge test and the modified Clinical and Laboratory Standards Institute (CLSI) ESBL confirmatory test in all isolates. Amplification of whole-cell and plasmid DNAs extracted from isolates with primers specific for the bla _KPC produced an amplicon confirmed to be bla _KPC-2 by sequence analysis. Pulsed-field gel electrophoresis (PFGE) typing revealed that three isolates belonged to two closely related types. Plasmids electrophoresis and restriction analysis revealed that the bla _KPC-2 was located on different plasmids. The transfer of carbapenem resistance from the three original isolates to Escherichia coli EC600 was successful by conjugation. An examination of the outer membrane proteins showed a lack of a 38-kDa outer membrane protein (OMP) compared with M. morganii susceptible to carbapenems. The production of KPC-2 and ESBLs, combined with OMP deficiency, resulted in high-level carbapenem resistance in the M. morganii strains. The genetic environment around bla _KPC-2 analysis revealed that this β-lactamase was located on the same mobile genetic elements which could transfer between different plasmids.     

Clonality and antimicrobial resistance gene profiles of multidrug- resistant Salmonella enterica serovar infantis isolates from four public hospitals in Rio de Janeiro, Brazil

In Brazil, Salmonella enterica serovar Infantis resistant to various antimicrobials, including cephalosporins, has been identified as an etiological agent of severe gastroenteritis in hospitalized children since 1994. In this study, 35 serovar Infantis strains, isolated from children admitted to four different Rio de Janeiro, Brazil, hospitals between 1996 and 2001, were characterized by pulsed-field gel electrophoresis (PFGE) and antimicrobial susceptibility testing in order to determine their genetic relatedness and antimicrobial resistance profiles. Thirty-four serovar Infantis strains were resistant to at least two antibiotic classes, and all 35 strains were susceptible to fluoroquinolones, cephamycin, and carbapenem. Extended-spectrum beta-lactamase (ESBL) screening by double-disk diffusion indicated that 32 serovar Infantis strains (91.4%) produced beta-lactamases that were inhibited by clavulanic acid. Antimicrobial resistance gene profiles were determined by PCR for a subset of 11 multidrug-resistant serovar Infantis strains, and putative ESBLs were detected by isoelectric focusing. Ten serovar Infantis strains carried bla(TEM), catI, ant(3")Ia and/or ant(3")Ib, sulI and/or sulII, and tet(D) genes as well as an integron-associated aac(6')-Iq cassette. Eight strains possessed at least four different beta-lactamases with pI profiles that confirmed the presence of both ESBLs and non-ESBLs. Our PFGE profiles indicated that 33 serovar Infantis strains isolated from Rio de Janeiro hospitals came from the same genetic lineage.     

Extended-spectrum beta-lactamase-producing Klebsiella spp

Extended-spectrum beta-lactamases (ESBLs) are associated particularly with Klebsiella spp. These enzymes have arisen by mutation of the genes coding for clavulanate-sensitive, plasmid-mediated beta-lactamases such as TEM-1, TEM-2 and SHV-1. Amino acid changes in ESBLs confer enhanced hydrolysis of oxyimino-aminothiazolyl beta-lactams and aztreonam. Enzyme hyperproduction and loss of porins contribute to hydrolytic efficiency. ESBLs are highly susceptible to inhibition by clavulanate, and their presence can be detected by the disc-approximation test, using amoxycillin/clavulanate and an ESBL-susceptible antibiotic. Other manual procedures have been used and commercial tests to detect the enzymes include Etest, Vitek and Dade Microscan products. The epidemiology of ESBLs is complex, and epidemic and sporadic strains may be encountered in the same hospital. Spread between hospitals--even countries--has been documented. ESBL activity is carried on large plasmids that often carry determinants for resistance to aminoglycosides and other antibiotics, and this is transmissible to Escherichia coli and other species of Enterobacteriaceae in which ESBLs have been detected.     

Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)

Emergence and dissemination of Enterobacteriaceae isolates harboring carbapenemases in various geographic regions represents a significant threat to the management of nosocomial infections. Enterobacteriaceae isolates from the SENTRY Antimicrobial Surveillance Program (2000-2004) demonstrating decreased susceptibility to imipenem and meropenem (minimum inhibitory concentration [MIC], > or =2 mg/L) were evaluated for the production of metallo-beta-lactamases and serine carbapenemases using disk approximation and polymerase chain reaction (PCR) tests. Carbapenemase-producing strains were epidemiologically typed by automated riboprinting and pulsed-field gel electrophoresis (PFGE) to establish clonality. Among 37,557 Enterobacteriaceae (5 genus groups) evaluated, 119 (0.32%) had increased carbapenem MIC values, and a carbapenemase was identified in 51 (42.9%) of these strains. KPC-2 and KPC-3 were the most frequently occurring carbapenemases (24 isolates, 20.2%) in the United States and were detected in Klebsiella spp, Citrobacter spp., Enterobacter spp., and Serratia marcescens strains isolated in New York, Arkansas, and Virginia. SME-2-producing S. marcescens were isolated in the New York City area, Texas, and Ohio, while NMC-A was found in one E. cloacae strain from New York. In contrast, metallo-beta-lactamases were prevalent in Europe. IMP-1-producing E. cloacae (11 isolates) were detected in Turkey, while VIM-1-producing strains were found in Italy (Enterobacter spp.) and Greece (Klebsiella pneumoniae). Clonal dissemination of carbapenemase-producing strains was observed in several medical centers on both continents. The occurrence of carbapenemases in various Enterobacteriaceae remains rare but appears to be spreading geographically (not in Latin America), mainly with metallo-beta-lactamases being found in Mediterranean Europe and KPC enzymes in the New York City area.     

Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002

Newer beta-lactamases such as extended-spectrum beta-lactamases (ESBLs), transferable AmpC beta-lactamases, and carbapenemases are associated with laboratory testing problems of false susceptibility that can lead to inappropriate therapy for infected patients. Because there appears to be a lack of awareness of these enzymes, a study was conducted during 2001 to 2002 in which 6,421 consecutive, nonduplicate clinical isolates of aerobically growing gram-negative bacilli from patients at 42 intensive care unit (ICU) and 21 non-ICU sites across the United States were tested on-site for antibiotic susceptibility. From these isolates, 746 screen-positive isolates (11.6%) were referred to a research facility and investigated to determine the prevalence of ESBLs in all gram-negative isolates, transferable AmpC beta-lactamases in Klebsiella pneumoniae, and carbapenemases in Enterobacteriaceae. The investigations involved phenotypic tests, isoelectric focusing, beta-lactamase inhibitor studies, spectrophotometric assays, induction assays, and molecular analyses. ESBLs were detected only in Enterobacteriaceae (4.9% of all Enterobacteriaceae) and were found in species other than those currently recommended for ESBL testing by the CLSI (formerly NCCLS). These isolates occurred at 74% of the ICU sites and 43% of the non-ICU sites. Transferable AmpC beta-lactamases were detected in 3.3% of K. pneumoniae isolates and at 16 of the 63 sites (25%) with no difference between ICU and non-ICU sites. Three sites submitted isolates that produced class A carbapenemases. No class B or D carbapenemases were detected. In conclusion, organisms producing ESBLs and transferable AmpC beta-lactamases were widespread. Clinical laboratories must be able to detect important beta-lactamases to ensure optimal patient care and infection control.     

儿童感染肺炎克雷伯菌产AmpC酶和ESBLs的检测及耐药性分析

目的了解广州地区儿童感染肺炎克雷伯菌产质粒介导的AmpC酶和超广谱β-内酰胺酶（ESBLs）的情况及其耐药特征,为临床合理用药提供参考依据。方法采用标准纸片扩散法检测ESBLs,头孢西丁三维试验法检测AmpC酶,K—B纸片法测定肺炎克雷伯菌对抗菌药物的敏感性。结果共检出248株肺炎克雷伯菌,其中46株产AmpC酶,阳性率为18．5％;157株产ESBLs,阳性率为63．3％;同时产AmpC酶和ESBLs菌株阳性率为18．1％。产AmpC酶肺炎克雷伯菌对第三代头孢菌素高度耐药。耐药率达80％～100％;对头孢吡肟、含酶抑制剂复合药的耐药率也在56．5％～93．5％之间：但对环丙沙星、阿米卡星的耐药率则在30％以下,对亚胺培南全部敏感。产ESBLs菌株对头孢菌素、含酶抑制剂复合药的耐药率也较高,在50％-91．7％之间,但对阿米卡星、环丙沙星、亚胺培南仍高度敏感。ESBLs阴性肺炎克雷伯菌对所测抗生素的敏感率均在81．2％以上。产酶菌株耐药率明显比非产酶菌株高。结论广州地区儿童感染肺炎克雷伯菌产ESBLs和AmpC酶的状况已十分突出：产酶菌株对常用抗生素的耐药率较高;碳青霉烯类抗生素可作为治疗产AmpC酶和／或ESBLs肺炎克雷伯菌感染的经验用药。